论文部分内容阅读
目的:研究金属硫蛋白(MT)和肿瘤增殖抗原(Ki-67)在卵巢上皮性肿瘤组织中的表达及相关性和临床意义。方法:采用免疫组化SP法及半定量分析法,检测105例卵巢上皮性肿瘤病理标本中的MT及Ki-67蛋白表达。结果:MT在卵巢癌及正常组织中表达有差异(P<0.01),Ki-67在不同组织学类型卵巢肿瘤间表达无明显差异(P>0.05);MT与Ki-67的表达强度恶性肿瘤高于正常、良性、交界性肿瘤(P<0.05),临床Ⅲ、Ⅳ期,病理2、3级的恶性肿瘤高于临床Ⅰ、Ⅱ期,病理1级者(P<0.01);MT与Ki-67的表达强度在恶性上皮性卵巢肿瘤中有显著相关性(P<0.05)。结论:组织中MT、Ki-67的表达强度与卵巢肿瘤的性质有关,MT和Ki-67可能作为卵巢肿瘤的预后预测参考指标。
Objective: To investigate the expression and clinical significance of metallothionein (MT) and tumor proliferation antigen (Ki-67) in ovarian epithelial tumor. Methods: Immunohistochemical SP method and semi-quantitative analysis were used to detect the expression of MT and Ki-67 in 105 specimens of ovarian epithelial tumor. Results: The expression of MT was significantly different between ovarian cancer and normal tissues (P <0.01). There was no significant difference in the expression of Ki-67 among different histological types of ovarian tumors (P> 0.05). The expressions of MT and Ki-67 in malignant tumors (P <0.05). The clinical stage Ⅲ and Ⅳ, pathological grade 2 and grade 3 malignant tumors were higher than those in clinical stage Ⅰ and Ⅱ and pathological grade 1 (P <0.01). The MT and Ki The expression intensity of -67 was significantly correlated with malignant ovarian tumors (P <0.05). Conclusion: The expression of MT and Ki-67 in tissues is related to the nature of ovarian tumors. MT and Ki-67 may serve as prognostic predictors of ovarian tumors.